The maximum amount of Neulasta^® that can be safely administered in single or multiple doses has not been determined. Single subcutaneous doses of 300 mcg/kg have been administered to 8 healthy volunteers and 3 patients with non small cell lung cancer without serious adverse effects. These patients experienced a mean maximum ANC of 55 x 10⁹/L, with a corresponding mean maximum WBC of 67 x 10⁹/L. The absolute maximum ANC observed was 96 x 10⁹/L with a corresponding absolute maximum WBC observed of 120 x 10⁹/L. The duration of leukocytosis ranged from 6 to 13 days. Leukapheresis should be considered in the management of symptomatic individuals.

Neulasta^® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, pegfilgrastim, Filgrastim, or any other component of the product.

Bookmark this page: